Trial · NCT06680622
Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
NCT06680622, Phase 2, Active not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy. Trials, record NCT06680622. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06680622
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
- NCT number
- NCT06680622
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 126 participants, estimated
- Lead sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Conditions
- Metastatic Gastro-esophageal Adenocarcinoma
- Interventions
- bemarituzumab, paclitaxel, ramucirumab, bemarituzumab, irinotecan, bemarituzumab, trifluridine/tipiracil
- First posted
- 2024-11-08
- Last updated
- 2026-01-07
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate (ORR) | from date of enrollment to date of last response acc. to RECIST v1.1 or death due to any cause, through study completion, up to 33 months | Objective response rate (ORR), defined as proportion of subjects with a complete response (CR) or partial response (PR) acc. to RECIST v1.1, for each cohort (cohort 1 - bemarituzumab plus irinotecan, cohort 2 - bemarituzumab plus paclitaxel and ramucirumab, cohort 3 - bemarituzumab plus trifluridine/tipiracil). |
| Secondary | Progression-free survival (PFS) | from date of enrollment to date of progression acc. to RECIST v1.1 or death due to any cause, through study completion, up to 33 months | Progression-free survival (PFS) |
| Secondary | Overall survival (OS) | time from date of enrollment to date of death due to any cause, through study completion, up to 33 months | Overall survival (OS) |
| Secondary | Disease control rate (DCR) | time from date of enrollment to date of last tumor assessment acc. to RECIST 1.1 or death due to any cause, through study completion, up to 33 months | proportion of subjects with CR, PR or stable disease (SD) according to RECIST v1.1 |
| Secondary | Duration of response (DoR) | time from response initiation (when either CR or PR is first determined) to date of progression or death to any cause, through study completion, up to 33 months | Duration of response (DoR) |
| Secondary | Disease stabilization | time from the first assessment of CR or PR or SD until the date of progression or death to any cause, through study completion, up to 33 months | Duration of disease stabilization |
| Secondary | Quality of Life (QoL) with EORTC QLQ C30 | time from baseline questionnaire to last filled questionnaire in follow up or until progression or death of any cause, through study completion, up to 33 months | Assessment of quality of life using EORTC QLQ C30 questionnaires during treatment |
| Secondary | Quality of Life (QoL) with EQ-5D-5L | time from baseline questionnaire to last filled questionnaire in follow up or until progression or death of any cause, through study completion, up to 33 months | Assessment of quality of life using EQ-5D-5L visual analogue scale (VAS) score |
| Secondary | Quality of Life (QoL) with HADS | time from baseline questionnaire to last filled questionnaire in follow up or until progression or death of any cause, through study completion, up to 33 months | Assessment anxiety/depression and satisfaction using HADS during treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06680622
GET https://conductscience.org/api/trials/v1/NCT06680622/registered